How Much Does Saxenda Cost in Wisconsin in 2026?

Saxenda Retail Pricing Across Wisconsin

The manufacturer list price set by Novo Nordisk for Saxenda is $1,349 per month, and that figure holds at most Wisconsin retail pharmacies in 2026. A single carton contains five pre-filled 3 mL pens, each delivering 6 mg/mL of liraglutide. At the maintenance dose of 3 mg daily, one carton lasts approximately 30 days.

Pricing differences between pharmacies in Wisconsin are small. Independent pharmacies in Milwaukee, Madison, and Green Bay typically list Saxenda within $20 of $1,349. Costco and select Walmart locations may offer slightly lower cash prices, but these discounts rarely exceed 5%. The real cost variation comes not from which pharmacy you choose but from which payment pathway you use: insurance, manufacturer savings programs, or compounded alternatives.

For context on the drug's clinical value at this price point, the SCALE Obesity and Prediabetes trial (N=3,731) demonstrated that liraglutide 3 mg produced 8.0% mean body weight loss over 56 weeks compared to 2.6% with placebo 1. More than 63% of participants on liraglutide lost at least 5% body weight, a threshold the FDA uses as a benchmark for clinical significance in obesity pharmacotherapy. That trial also showed a 79% reduction in prediabetes-to-diabetes conversion at 3 years among the liraglutide group, a finding with direct cost implications for long-term metabolic health.

Wisconsin Medicaid Coverage for Saxenda

Wisconsin Medicaid does cover Saxenda. The requirement is prior authorization.

To obtain prior authorization through Wisconsin's Medicaid program (BadgerCare Plus and fee-for-service), prescribers must document that the patient has a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. The prescriber also needs to show that lifestyle modifications alone have been insufficient, typically defined as a structured diet and exercise program followed for at least 3 to 6 months without adequate weight loss.

Processing times for prior authorization vary. Standard requests through Wisconsin's Medicaid pharmacy benefit manager are typically reviewed within 24 to 72 hours. Urgent requests may be processed the same day. If denied, patients and providers can appeal the decision. The Endocrine Society's 2015 clinical practice guideline recommends pharmacotherapy for patients meeting these BMI thresholds, which supports the medical necessity argument in appeals.

Wisconsin Medicaid managed care organizations, including Quartz, Molina Healthcare, and Dean Health Plan, each maintain their own formulary rules for Saxenda. Some MCOs place Saxenda on a specialty tier with higher cost-sharing. Others require step therapy, meaning patients must first try and fail a less expensive weight-management medication before Saxenda is approved. Calling the MCO's pharmacy helpline before submitting the PA request can save weeks of back-and-forth.

Commercial Insurance Coverage in Wisconsin

Private insurers in Wisconsin handle Saxenda coverage inconsistently. Large employers offering self-funded plans through carriers like Anthem, UnitedHealthcare, and Humana increasingly include GLP-1 receptor agonists for weight management on their formularies, but coverage is far from universal.

The situation breaks down roughly like this. Plans that explicitly exclude "weight loss drugs" will deny Saxenda regardless of clinical justification. Plans that cover anti-obesity medications typically require prior authorization with documentation of BMI, comorbidities, and failed lifestyle intervention. A smaller subset of plans cover Saxenda without PA, though this is uncommon.

Patients enrolled in Marketplace (ACA) plans purchased through HealthCare.gov in Wisconsin should check their plan's Summary of Benefits and Coverage document. Wisconsin does not mandate that ACA plans cover anti-obesity medications, so coverage depends entirely on the insurer and plan tier. According to the American Association of Clinical Endocrinology (AACE) obesity treatment algorithm, pharmacotherapy is a recommended second-line intervention, and citing this guideline in appeals can strengthen the case for coverage.

Copay amounts for commercially insured Wisconsin patients with Saxenda coverage range widely. Preferred formulary placement may yield copays of $50 to $150 per month. Non-preferred or specialty tier placement can push copays to $200 to $400. Without any coverage, patients pay the full $1,349.

The Novo Nordisk Savings Card

Novo Nordisk offers a manufacturer savings card for Saxenda that can reduce out-of-pocket costs by up to $200 per 30-day fill. The card is available to commercially insured patients who have a valid prescription. It cannot be used with government insurance programs including Medicaid, Medicare, TRICARE, or VA benefits.

Eligibility is straightforward. Patients must be 18 or older, have commercial insurance, and fill their prescription at a participating pharmacy. Nearly all major chain and independent pharmacies in Wisconsin accept the card. Activation is done online through the Novo Nordisk patient support website or by calling their support line.

The savings card effectively drops the monthly out-of-pocket cost for many commercially insured Wisconsin patients. If a patient's insurance copay is $250 per month, the savings card brings it to $50. If the copay is $150, the card brings it to zero (since the card covers up to $200 of the copay). The card does not apply to the portion of cost covered by insurance, only the patient's out-of-pocket share. The program terms can change, so patients should verify current benefits at the time of each fill.

For patients paying full cash price without insurance, the savings card provides limited relief. Reducing $1,349 by $200 still leaves $1,149 per month, which remains prohibitive for most households. These patients may benefit more from compounded alternatives.

Compounded Liraglutide 3 mg in Wisconsin

Compounded liraglutide 3 mg is available in Wisconsin through licensed 503A compounding pharmacies. This is legal under federal law.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed compounding pharmacies to prepare patient-specific formulations of FDA-approved drugs when a valid prescription exists 2. The Wisconsin Department of Safety and Professional Services licenses compounding pharmacies operating within the state, and several 503A facilities currently compound liraglutide 3 mg for subcutaneous injection.

The cost difference is significant. While brand-name Saxenda runs $1,349 per month, compounded liraglutide through a 503A pharmacy can cost substantially less, with some telehealth platforms offering it at a fraction of the brand price. Pricing varies by pharmacy and whether the patient accesses it through a telehealth provider or a local compounding pharmacy.

There are considerations patients should understand. Compounded medications are not FDA-approved products. They do not undergo the same manufacturing review process as commercially manufactured drugs. The FDA has stated that compounded drugs can serve an important medical need but carry different risk profiles than approved products. Patients should verify that any compounding pharmacy they use holds a current Wisconsin pharmacy license and follows USP 797 sterile compounding standards.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has noted: "When patients cannot afford brand-name GLP-1 therapies, compounded versions from reputable pharmacies can help bridge the access gap, but patients should work with their physician to ensure quality and appropriate dosing."

Telehealth Access to Saxenda in Wisconsin

Telehealth prescribing of Saxenda is fully legal in Wisconsin. The state's telehealth parity laws, updated during and after the COVID-19 public health emergency, allow licensed prescribers to evaluate patients and write prescriptions for controlled and non-controlled medications via video or audio-visual consultation.

Several national telehealth platforms now serve Wisconsin patients seeking Saxenda or compounded liraglutide prescriptions. These platforms typically charge a consultation fee ranging from $50 to $199, with some rolling the cost into a monthly subscription that includes the medication. The consultation involves a medical history review, BMI assessment, and discussion of weight-management goals and contraindications.

Wisconsin does not require an in-person visit before a telehealth prescriber can write a Saxenda prescription. The prescriber must hold a valid Wisconsin medical license or practice under a multistate compact agreement. This opens access for patients in rural parts of the state, including northern Wisconsin communities where obesity medicine specialists are scarce. According to the CDC, Wisconsin's adult obesity prevalence was 36.2% in the most recent survey period, making access to evidence-based pharmacotherapy a pressing public health concern across the state.

Prescriptions written via telehealth can be filled at any Wisconsin pharmacy, including compounding pharmacies. Some telehealth platforms have integrated pharmacy partnerships that ship directly to the patient's home, which eliminates an additional step.

How to Reduce Your Saxenda Cost in Wisconsin

The gap between $1,349 and what patients actually pay depends on which cost-reduction strategies they layer together. Here is a practical breakdown.

Step 1: Check your insurance formulary. Call the member services number on the back of your insurance card and ask whether Saxenda (liraglutide 3 mg) is on formulary. If yes, ask about tier placement, prior authorization requirements, and estimated copay. If no, ask whether any anti-obesity medications are covered, since some plans cover Wegovy (semaglutide 2.4 mg) but not Saxenda, or vice versa.

Step 2: Apply the Novo Nordisk savings card. If you have commercial insurance and Saxenda is covered, activate the savings card before your first fill. This can reduce copays by up to $200 per month.

Step 3: Request prior authorization proactively. Do not wait for a pharmacy rejection. Ask your prescriber to submit the PA with your initial prescription. Include documentation of BMI, comorbidities, and prior lifestyle interventions. The AAFP recommends that primary care physicians initiate pharmacotherapy discussions with patients meeting BMI criteria, which supports early PA submission.

Step 4: Explore compounded liraglutide. If insurance does not cover Saxenda or your copay remains unaffordable after applying the savings card, ask your prescriber about compounded liraglutide 3 mg from a licensed Wisconsin 503A pharmacy. This option offers the same active ingredient at lower cost.

Step 5: Compare pharmacy prices. Use pharmacy price comparison tools to check Saxenda pricing at Wisconsin pharmacies near you. While variation is modest for brand-name Saxenda, compounded liraglutide pricing can differ substantially between pharmacies.

The SCALE trial data showing 8.0% mean weight loss over 56 weeks 1 and the documented reduction in cardiometabolic risk factors, including a mean reduction in HbA1c of 0.3 percentage points and systolic blood pressure of 4.2 mmHg in the treatment group, support the clinical and economic argument for coverage. Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine, has stated: "The cost of not treating obesity far exceeds the cost of pharmacotherapy when you account for downstream diabetes, cardiovascular events, and joint replacements."

Saxenda Dosing and What a Month's Supply Looks Like

Saxenda follows a 4-week titration schedule before reaching the target dose. Patients begin at 0.6 mg daily for one week, increase to 1.2 mg in week two, 1.8 mg in week three, 2.4 mg in week four, and reach the maintenance dose of 3.0 mg daily from week five onward 3. This means the first month's carton lasts longer than 30 days because the patient uses less medication per injection during titration.

Each Saxenda pen contains 18 mg of liraglutide in 3 mL. At the 3.0 mg maintenance dose, one pen lasts 6 days. Five pens per carton deliver a 30-day supply. During the titration month, patients use roughly 63 mg total rather than the full 90 mg (30 days at 3 mg), so the initial carton may stretch to approximately 6 weeks.

This titration math matters for Wisconsin patients managing cost. The first month effectively costs less per day of treatment. Patients who tolerate the drug well and continue to maintenance dosing should plan on one carton per month going forward at whatever price they have secured through insurance, savings card, or compounding.

Common side effects during titration include nausea (reported by 39.3% of participants in SCALE), diarrhea, constipation, and injection-site reactions 1. Most nausea is mild to moderate and diminishes after the first 4 to 8 weeks. The slow titration schedule exists specifically to minimize gastrointestinal side effects.

Wisconsin-Specific Resources and Next Steps

Wisconsin patients can access Saxenda through their primary care provider, an endocrinologist, or an obesity medicine specialist. The state has board-certified obesity medicine physicians in Milwaukee, Madison, Eau Claire, Appleton, and La Crosse, among other cities. The American Board of Obesity Medicine maintains a provider directory searchable by zip code.

For patients preferring telehealth, multiple platforms licensed in Wisconsin can prescribe Saxenda or compounded liraglutide after a virtual consultation. Wisconsin's Medicaid program also covers telehealth visits, meaning BadgerCare Plus enrollees can potentially obtain both the consultation and the medication through covered channels.

Patients starting Saxenda should have baseline labs drawn including fasting glucose, HbA1c, lipid panel, and thyroid function. Liraglutide carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies, though no causal link has been established in humans 3. The drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Wisconsin prescribers should document thyroid history before initiating therapy, and patients with a calcitonin level above 50 pg/mL at baseline require further evaluation before starting treatment.